Apnimed, Inc.(APMD)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Apnimed, Inc. (APMD) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores APMD at 34.3/100 on a 32-signal composite quality model, placing it at rank #2,355 of 2,961 stocks — the bottom half of the AI-ranked universe. APMD scores in the top quartile across balance sheet strength (94.0). Areas of concern include revenue growth (2.5) and profitability (30.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 30.0/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Apnimed, Inc. reports quarterly revenue of $12.1M, net income of $125.9M, an operating margin of -96.9%. APMD trades on the Nasdaq exchange and files with the SEC under CIK 1745648. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate APMD daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Apnimed, Inc. directly from SEC EDGAR.